ROBOSENSE-LIDAR
29.7.2021 14:02:14 CEST | Business Wire | Press release
RoboSense LiDAR , the leading Smart LiDAR Sensor provider and GAC Aion New Energy Automobile Co., Ltd. (“GAC Aion”) set up by Guangzhou Automobile Group Co., Ltd (GAC Group，6601238.SH，02238.HK) , a Fortune 500 company and one of the automobile groups with the most complete industry chain in China jointly announced that GAC has selected RoboSense's second-generation intelligent solid-state LiDAR equipped with the ADiGO autonomous driving system，and will be mass-produced on a variety of autonomous driving models including the Aion LX of GAC Aion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005558/en/
ADiGO is an intelligent driving ecosystem led by GAC. This independently developed and interconnected ecosystem integrates smart factory, autopilot system, and IoT system. Powered by big data and various AI technologies, the self-driving system is available for mass production in L3 and is able to support L4 pilot running in some closed scenarios. The current ADiGO system on the Aion LX and Aion V uses a triple perception system (camera, millimeter wave radar, high-precision map) to achieve L3 autonomous driving in highway and urban expressway scenes.
The characteristics of Robosense's second-generation LiDAR active high-precision three-dimensional perception allows the ADiGO system to obtain more reliable perception information and ensure driving safety. It adopts a revolutionary two-dimensional MEMS smart chip scanning architecture and has a unique intelligent "GAZE" function, which can adjust the scanning method according to the driving scene, improve the perception of LiDAR, and help improve the performance and experience of autonomous driving. While achieving hardware intelligence verification, RS-LiDAR-Algorithm, the core of software intelligence, has more than 13-years of technology research and development accumulation. During the 5-year commercialization of LiDAR products, it has been verified by more than 100 partners in multiple scenarios around the world. Internally integrated AI perception algorithm, synchronously output 3D point cloud data and target-level environment perception results. The second-generation intelligent solid-state LiDAR helps the ADiGO system achieve a leap from safety to comfort in the driving experience under various road conditions.
In high-speed scenes, intelligent “GAZE” dynamically increases the vertical resolution of the ROI area, allowing the ADiGO system to find distant obstacles earlier, and enhance the autonomous driving experience on highways and urban expressways. In urban scenes, intelligent “GAZE” dynamically improves refresh the frame rate helps the ADiGO system respond more quickly to the dynamic changes of surrounding vehicles，pedestrians and other obstacles.
Due to technological innovation, the second-generation intelligent LiDAR can effectively control hardware costs, allowing more consumers to obtain a safer and more comfortable experience of autonomous driving. In the future, RoboSense will continue to promote technological innovation. Through the sustainable upgrad of intelligent LiDAR product system solution, it will work with partners to promote the intelligent car ecosystem.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.
About GAC Motor (https://www.gac-motor.com ):
Guangzhou Automobile Group Co., Ltd. (“GAC”) was incorporated in June 1997. In 2020, GAC’s production and sales both exceeded 2 million, with a positive year-on-year growth. Based on export planning, GAC Group successfully pushed ahead its international business, and GAC MOTOR was born with the right time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom